SCHEMBL20224898

SCHEMBL20224898

Cn1cc(Cl)c2c(=O)[nH]cnc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 2/20 0.44
CCNE2 O96020 1/20 0.44
CDK4 P11802 1/20 0.44
CCND1 P24385 1/20 0.44
CCNE1 P24864 1/20 0.44
PARP1 P09874 3/20 0.44
ALDH1A1 P00352 1/20 0.44
SRC P12931 1/20 0.40
MAPT P10636 4/20 0.39
LMNA P02545 2/20 0.39
HTT P42858 1/20 0.39
ATAD2 Q6PL18 1/20 0.38
AURKA O14965 2/20 0.37
DAPK3 O43293 2/20 0.37
PRKD3 O94806 2/20 0.37
MAP4K4 O95819 2/20 0.37
RET P07949 2/20 0.37
IGF1R P08069 2/20 0.37
PIM1 P11309 2/20 0.37
CLK2 P49760 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15265574 0.79 ALDH1A1 (0.44) CDK2CCNE2CDK4CCND1CCNE1
SCHEMBL20224829 0.79 PARP1 (0.44) PARP1ALDH1A1SRCMAPTLMNA
SCHEMBL24218741 0.79 CDK2 (0.41) CDK2CCNE2CDK4CCND1CCNE1
SCHEMBL20224906 0.79 CCNE2 (0.41) CDK2CCNE2CDK4CCND1CCNE1
SCHEMBL23228188 0.76 CDK2 (0.40) CDK2CCNE2CDK4CCND1CCNE1
SCHEMBL15265113 0.74 SRC (0.68) ALDH1A1SRCMAPTLMNAHTT
SCHEMBL20224896 0.71 ADORA2A (0.41) LMNAMAP2K1PIK3CDADORA3PDE4A
SCHEMBL4626229 0.71 CRHR1 (0.47) PARP1ALDH1A1SRCMAPTLMNA
SCHEMBL1528682 0.69 ATAD2 (0.41) CDK2CCNE2CDK4CCND1CCNE1
SCHEMBL13192053 0.68 ADORA2A (0.46) SRCHTTDAPK3BTKDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4242212-A2 STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING Takeda Pharmaceutical Company Limited (JP) 2023-09-13 EP disclosed
US-20230149560-A1 LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. 2023-05-18 US disclosed
WO-2021216572-A1 LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2021-10-28 WO disclosed
US-20210106607-A1 ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-04-15 US disclosed
US-20210015915-A1 STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-01-21 US disclosed
WO-2020065408-A1 SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES PIERRE FABRE MEDICAMENT (FR) 2020-04-02 WO disclosed
WO-2018100558-A2 CYCLIC DINUCLEOTIDE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149560-A1 LIPID COMPOSITIONS FOR DELIVERY OF STING AGONIST COMPOUNDS AND USES THEREOF STING1, CGAS, TLR9 CDK2 4849/4885CCNE2 4615/4885CDK4 4487/4885
US-20210106607-A1 ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE STING1, TLR9, CGAS CDK2 4868/4885CCNE2 4882/4885CDK4 4865/4885
US-20210015915-A1 STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING STING1, CGAS, TBK1 CDK2 4755/4885CCNE2 4863/4885CDK4 4804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.